Table 2

Baseline Clinical and Angiographic Characteristics of Patients Randomized to Bivalirudin or Heparin Plus GPI

All (n = 2,530)Bivalirudin (n = 1,245)Heparin Plus GPI (n = 1,285)p Value
Age, yrs60.5 ± 11.460.2 ± 11.560.8 ± 11.40.206
Men1,955 (77.3%)971 (78%)984 (76.6%)0.396
Diabetes mellitus402 (15.9%)184 (14.8%)218 (17.0%)0.133
Hypertension1,339 (52.9%)630 (50.6%)709 (55.2%)0.021
Hyperlipidemia1,088 (43.0%)540 (43.4%)548 (42.6%)0.712
Current smoking1,196 (47.3%)619 (49.8%)577 (44. 9%)0.013
Prior MI98 (3.9%)44 (3.5%)54 (4.2%)0.384
Prior CABG59 (2.3%)34 (2.7%)25 (1.9%)0.191
Body mass index, kg/m227.7 ± 4.627.7 ± 4.727.7 ± 4.60.875
Symptom onset to PCI, h5.2 ± 16.45.5 ± 22.15.0 ± 7.50.593
Killip class 2/4208 (8.2%)103 (8.3%)105 (8.2%)0.926
Creatinine clearance <60 ml/min383 (15.1%)173 (13.9%)210 (16.3%)0.086
Anemia249 (9.8%)121 (9.7%)128 (10.0%)0.830
≥3 diseased vessels614 (24.3%)304 (24.4%)310 (24.1%)0.864
Anterior infarct location1,720 (68.0%)835 (67.1%)885 (68.9%)0.331
Initial TIMI flow grade 3337 (13.4%)163 (13.1%)174 (13.6%)0.752
LVEF <0.40348 (13.8%)155 (12.4%)193 (15.0%)0.061
Stent implanted2,471 (97.7%)1,221 (98.1%)1,250 (97.3%)0.185
Final TIMI flow grade <3335 (13.2%)166 (13.3%)169 (13.2%)0.893

Values presented as n (%) or mean ± SD unless otherwise noted.

GPI = glycoprotein IIb/IIIa inhibitors; other abbreviations as in Table 1.